2025-04-03 13:31:17
Latest Post
Gland Pharma receives approval for Acetaminophen Injection
Amneal Pharmaceuticals launches 2nd NDA Bortezomib for injection3.5mg/1.4ml in US 
Medicamen Biotech Limited signs CDMO contract with XGX Pharma
Thomas Cook India's Foreign Exchange business appoints Bollywood star Kartik Aaryan as Brand Ambassador
IDFC FIRST Bank Limited Q4, FY2025 Business Update
Stock Report
Bata India Ltd Q2 FY2025 consolidated PAT at Rs. 51.97 crores
Posted On : 2024-11-04 19:58:21( TIMEZONE : IST )
Bata India Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 854.329 crores during the period ended September 30, 2024 as compared to Rs. 960.869 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 51.979 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 174.063 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 4.04 for the period ended September 30, 2024 as compared to Rs. 13.54 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 854.329 crs | ₹960.869 crs |  -11.09% |
| Net Profit | ₹51.979 crs | ₹174.063 crs | -70.14% |
| EPS | ₹4.04 | ₹13.54 | -70.16% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 854.329 crores during the period ended September 30, 2024 as compared to Rs.834.617 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.51.979 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.33.993 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.4.04 for the period ended September 30, 2024 as compared to Rs.2.61 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 854.329 crs | ₹834.617 crs |  2.36% |
| Net Profit | ₹51.979 crs | ₹33.993 crs | 52.91% |
| EPS | ₹4.04 | ₹2.61 | 54.79% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.1815.198 crores during the 6 Months period ended September 30, 2024 as compared to Rs.1806.038 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.226.012 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.140.885 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.17.59 for the 6 Months period ended September 30, 2024 as compared to Rs.10.96 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹1815.198 crs | ₹1806.038 crs | 0.51% |
| Net Profit | ₹226.012 crs | ₹140.885 crs | 60.42% |
| EPS | ₹17.59 | ₹10.96 | 60.49% |
Shares of Bata India Limited was last trading in BSE at Rs. 1336.90 as compared to the previous close of Rs. 1356.90. The total number of shares traded during the day was 15468 in over 2773 trades.
The stock hit an intraday high of Rs. 1360.90 and intraday low of 1330.60. The net turnover during the day was Rs. 20773584.00.
